Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
about
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
description
2017 nî lūn-bûn
@nan
2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Comparing biosimilar SB2 with ...... structural and safety results.
@en
Comparing biosimilar SB2 with ...... structural and safety results.
@nl
type
label
Comparing biosimilar SB2 with ...... structural and safety results.
@en
Comparing biosimilar SB2 with ...... structural and safety results.
@nl
prefLabel
Comparing biosimilar SB2 with ...... structural and safety results.
@en
Comparing biosimilar SB2 with ...... structural and safety results.
@nl
P2093
P2860
P356
P1433
P1476
Comparing biosimilar SB2 with ...... structural and safety results.
@en
P2093
Agnieszka Zielinska
Asta Baranauskaite
Eva Dokoupilova
Hana Ciferska
Ivan Staykov
Jaroslaw Niebrzydowski
Jasmine Choi
Jung-Yoon Choe
Krystyna Jedrychowicz-Rosiak
Mevludin Mekic
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEX254
P577
2017-10-01T00:00:00Z